Core Insights - The report emphasizes the investment strategy for the pharmaceutical and biotechnology industry, particularly focusing on undervalued stocks in the medical device and pharmacy sectors, which are expected to experience a valuation reversal [1][5]. - The overall investment rating for the sector is maintained at "outperform the market" [2]. Industry Overview - The pharmaceutical manufacturing industry showed a cumulative revenue of 18,211 billion yuan with a year-on-year decline of 2.0% for the first nine months of 2025 [8]. - The total profit for the industry during the same period was 2,535 billion yuan, reflecting a decrease of 0.7% [8]. - The retail sales of Western and Chinese medicines reached 535.1 billion yuan, with a growth of 1.3% year-on-year [8]. Sector Performance - In October 2025, the pharmaceutical sector experienced an overall decline of 1.83%, underperforming the CSI 300 index by the same margin [9]. - Among sub-sectors, the pharmaceutical commercial sector saw an increase of 2.81%, while the medical services sector faced a decline of 4.14% [14]. Investment Strategy - The report recommends focusing on low-valuation stocks in the medical device and pharmacy sectors, highlighting companies such as Weigao Group, Yifeng Pharmacy, and Mindray Medical [5]. - The CXO sector is identified as having global competitiveness, with a strong long-term growth trajectory [5]. Company Recommendations - The investment portfolio for November 2025 includes A-shares such as Mindray Medical, WuXi AppTec, and Yeye Medical, and H-shares like Kangfang Biologics and Kelun-Botai [5][6]. - Specific companies are highlighted for their growth potential, including WuXi AppTec, which is expected to see significant revenue growth in the coming quarters [5]. Regulatory Environment - The report tracks ongoing centralized procurement projects for medical devices, indicating a structured approach to managing costs and ensuring compliance within the industry [29].

Market Performance - The pharmaceutical and biotechnology index declined by 2.62% from November 3 to November 7, underperforming the Shanghai Composite Index by 2.37 percentage points, marking seven consecutive weeks of underperformance [1] - The innovative drug sector (BK1106) fell by 3.51% during the week, while the Hang Seng Healthcare Index dropped by 2.39% and the Hong Kong innovative drug ETF (513120) decreased by 3.92% [1] Industry Commentary - After a strong rally, the innovative drug industry has entered a bubble-popping phase, with a return to rational investment not necessarily being negative for the sector. However, the current market adjustment appears excessive, with leading companies like Kangfang Biotech, Zai Lab, and Kelun-Biotech experiencing declines exceeding 30% [2] - Zai Lab's recent performance has been impacted by two public announcements: disappointing clinical data for its gastric cancer drug Bemarituzumab and a Q3 report showing total revenue of $116 million, a 14% year-on-year increase, but a net loss of $35.96 million, which is a narrowing of losses compared to the previous year. Revenue growth was primarily driven by sales of "Nusinersan" and "Dingyoule," offset by a slowdown in "Zele" sales [2] Short-term Outlook - In the short term, the innovative drug industry is undergoing emotional recovery and valuation reconstruction, with stock volatility heavily influenced by clinical data and earnings guidance. Zai Lab faces short-term emotional pressure due to the termination of a key clinical trial and downward adjustments in performance expectations. However, from a medium to long-term perspective, the innovative logic of the industry remains unchanged, with globally competitive pipeline assets being the core support for company valuations [3] IPO Developments - Nanjing Haina Pharmaceutical Technology Co., Ltd. has submitted an IPO application to the Hong Kong Stock Exchange, with CICC as the sole sponsor. This follows the termination of a major asset restructuring plan in June 2023, where Haina was to be acquired by Chengdu Xian Dao [4] - Haina Pharmaceutical, established in 2001, integrates drug research and manufacturing, providing CXO services and proprietary product pipelines. The company's revenue primarily comes from CXO services, with 398 ongoing CXO projects as of mid-2025 [4] Financial Performance - For 2024, Haina Pharmaceutical projects revenue of 425 million yuan, a year-on-year increase of 3.65%, but a net profit of 53.295 million yuan, reflecting a 27% decline, indicating a situation of "increased revenue but decreased profit." In the first half of the year, both revenue and net profit saw declines of 16.97% and 25.82%, respectively, attributed to a decrease in CRO service income and a 45.8% drop in sales of proprietary drugs [5] Clinical Trial Updates - From November 3 to November 7, the National Medical Products Administration disclosed 110 new clinical trial registrations, with 33 of these being innovative drugs in Phase II or above, primarily covering oncology, immunology, cardiovascular, and psychiatric fields [6] - Four innovative drugs were approved during the week [7] Notable Approvals - The first CAR-T therapy in China, Pucalunase injection (pCAR-19B), was approved for treating pediatric acute B lymphoblastic leukemia patients aged 3 to 21. This drug was previously included in breakthrough therapy and priority review categories [8] - Pucalunase is the fifth CD19 CAR-T product approved in China, following four others from various companies [9]

Group 1 - The core viewpoint of the article highlights the recent performance of the innovative drug sector, indicating a market correction phase after a strong rally, with significant declines in stock prices for leading companies like 康方生物 and 再鼎医药 [5][6][4] - The innovative drug index and related ETFs have shown declines, with the Hang Seng Healthcare Index down by 2.39% and the Hong Kong innovative drug ETF down by 3.92% over the week [4][5] - Recent clinical trial results for 再鼎医药's gastric cancer drug 贝玛妥珠单抗 were disappointing, leading to a halt in its clinical study due to insufficient efficacy [5][6] Group 2 - 海纳医药 has submitted an IPO application to the Hong Kong Stock Exchange after failing to complete a major asset restructuring to enter the A-share market [7][8] - The company primarily generates revenue from its CXO services, with 398 ongoing CXO projects as of mid-2025 [7] - 海纳医药's revenue for 2024 is projected at 425 million yuan, reflecting a year-on-year growth of 3.65%, but its net profit is expected to decline by 27% [8] Group 3 - The first CAR-T therapy for treating pediatric leukemia, 普基仑赛, has been approved for market release in China, marking a significant milestone in innovative drug development [13][12] - The approval of 普基仑赛 follows a series of clinical trials and regulatory reviews, emphasizing its potential in treating acute B-cell leukemia in children aged 3 to 21 [13][12] - The article notes that this is the fifth CD19-targeting CAR-T product approved in China, indicating a growing market for such therapies [14]

Core Viewpoint - The investment opportunities in the pharmaceutical industry for 2026 are highlighted, particularly in innovative medical devices, innovative drugs, and high-growth CXO and upstream life sciences companies [1] Group 1: Investment Opportunities - Innovative medical devices are identified as a focus area, contingent on performance alignment [1] - After a correction in innovative drugs, certain high-quality targets are recommended for attention [1] - High-growth CXO and upstream life sciences companies are also considered worthy of attention if they can maintain robust business growth [1] Group 2: Market Conditions - The pharmaceutical sector has been at a low point since peaking in 2021, presenting current investment opportunities [1] - Institutional investors may reallocate resources when the fundamentals of pharmaceutical companies improve and performance aligns [1] Group 3: Stock Selection Strategy - The company aims to identify and predict significant turning points in the lifecycle of industries and companies [1] - The strategy involves early market positioning to capture excess returns as industry and company values become recognized, leading to simultaneous performance and valuation increases [1] - A preference for innovative drug industry chains (CXO, upstream life sciences) as a high-probability offensive base, while positioning medical devices as a defensive allocation [1]

"展望未来，创新药仍是值得关注的一个重要细分赛道，但是标的上需要精挑细选，估值方面也会趋于 理性。"丁天宇表示，"整个医药板块除了创新药及产业链外，其他赛道估值相对较低，随着基本面逐步 好转，医药板块有望涌现更多的投资机会。" 中证报中证网讯(记者王雪青)11月11日晚间，中金基金权益部基金经理丁天宇在"中证点金汇"直播间表 示，近期创新药板块回调，一方面是前期预期过高，一些临床早期项目被给予了全球数十亿美元的市场 估值，几个大BD(业务拓展，常指海外授权)拉高了市场对潜在BD项目的预期，且有几个50亿美元以上 的BD项目预期下半年可能落地；另一方面是三季度开始，创新药的催化事件变少，超预期数据发布较 少，预期中的大型BD项目也推迟或不及预期，进而导致板块回调。 ...

Core Insights - The report emphasizes the investment strategy for the pharmaceutical and biotechnology industry, focusing on undervalued targets in the medical device and pharmacy sectors, which are expected to experience a valuation reversal [1][5]. - The overall investment rating for the sector is maintained at "outperform the market" [2]. Industry Performance Review - The pharmaceutical industry experienced a decline of 1.83% in October, underperforming the CSI 300 index by the same margin [9]. - The medical manufacturing sector reported a cumulative revenue of 1.8211 trillion yuan, down 2.0% year-on-year, with a total profit of 253.5 billion yuan, a decrease of 0.7% [8]. Sector Analysis - The report categorizes the CXO sector into three segments: CDMO, preclinical and clinical CRO, and generic drug CXO, highlighting the growth potential in each area [5]. - The CDMO segment shows promising growth with significant increases in new orders and emerging business areas such as peptides and oligonucleotides [5]. - The preclinical and clinical CRO segment is recovering with new order prices showing an upward trend [5]. - The generic drug CXO segment is facing challenges due to a reduced number of MAH clients and is actively seeking new growth points through innovation [5]. Investment Strategy - The report recommends focusing on undervalued medical device and distribution stocks, as well as the long-term positive trend in innovative drugs and their supply chains [5]. - A specific investment portfolio for November 2025 includes companies such as Mindray Medical, WuXi AppTec, and Aier Eye Hospital, among others [5][6]. Recent Developments - In October 2025, six innovative drugs or biosimilars were approved for market entry, indicating a robust pipeline for the industry [23][24]. - The report tracks ongoing centralized procurement initiatives for medical devices, which are expected to impact pricing and market dynamics [29]. Valuation Insights - The overall valuation of the pharmaceutical sector is currently at a PE (TTM) of 38.80, which is at the 81.52% historical percentile over the past five years, indicating a relatively high valuation compared to historical averages [17].

二级市场方面，本轮调整在时间和空间维度都较为充分。历史上，创新药指数的回调平均时长在30-40 天，幅度在20%附近。少数几次跌破阈值的行情都伴随极端事件比如加息、疫情透支这种罕见事件。而 在创新药产业趋势确定的背景下，本轮调整时长已近一个季度，指数跌幅已超过20%。此外，大型配置 型机构除在年底纷纷止盈外，也需要为明年布局。 获益于资金坚定逆行增仓，港股通创新药ETF（520880）份额与规模逆市增长。11月3日，基金规模首 次突破20亿元，自7月7日上市以来猛增392%！11月10日，基金份额升至37.84亿份，续创上市新高！ 立足当下，如何看待创新药本轮调整，操作层面又该何去何从？ 港股通创新药ETF（520880）基金经理丰晨成最新重申：创新药行情可能随时开启，当下或处于高胜率 区间。 创新药本轮调整可能仍在寻底。从创新药含量100%的港股通创新药ETF（520880）走势来看，11月以 来多次反抽，但行情尚缺持续性，单周内表现多涨跌互现。本周，周一（11月10日）反弹1.28%，周二 又回调0.54%。 创新药还能买吗？资金用脚投票。港股通创新药ETF（520880）资金动向与行情走势截然相反，9月 ...

Group 1: Cement Industry - The cement sector's profitability is primarily driven by overseas performance, particularly in regions like Africa, where companies such as Huaxin Cement are seeing significant advantages [3] - Domestic demand and prices have weakened compared to Q2, indicating a potential bottoming out in 2024, with supply-side restrictions being a key focus for industry improvement [3] - Shareholder returns are expected to improve due to industry stock incentive plans [3] Group 2: Consumer Building Materials - There is a noticeable divergence in revenue growth rates among various sub-sectors and companies within the consumer building materials industry, influenced by real estate and local debt issues [4] - Companies are exploring new revenue paths through overseas expansion, market penetration, and renovation projects [4] - Price recovery and structural upgrades in the paint and waterproofing sectors are leading the way, although full realization will take time [4] Group 3: Glass and Fiberglass - The fiberglass industry is experiencing dual differentiation in production and sales, with larger companies maintaining better performance amid price wars [5] - The glass sector is nearing a turning point, with float glass prices stabilizing and photovoltaic glass showing signs of recovery due to industry self-discipline in production cuts [5] - The market characteristics of the glass sector, dominated by private enterprises, contribute to a more effective market-driven clearing mechanism [5]

Investment Rating - The investment rating for the biopharmaceutical industry is "Outperform the Market" (maintained) [2] Core Insights - The biopharmaceutical industry in A-shares has shown marginal improvement in revenue and profit performance in Q3 2025, with a continued high prosperity in innovative drugs and the industry chain [6][7] - The innovative drug sector has demonstrated robust growth, with a revenue increase of 21.41% year-on-year in the first three quarters of 2025, while the CXO sector also showed significant growth [6][10] - There is a focus on undervalued turnaround targets in the medical device and pharmacy sectors, which have shown signs of stabilization and recovery [6][20] Summary by Sections Financial Summary - In the first three quarters of 2025, A-share pharmaceutical companies achieved a total revenue of 17,480.2 billion yuan, a year-on-year decrease of 1.22%, and a net profit of 1,355.8 billion yuan, down 1.00% year-on-year [6][7] - The innovative drug sector generated revenue of 485.6 billion yuan (+21.41%) and a net profit of -4.6 billion yuan, significantly reducing losses [6][10] - The CXO sector reported revenue of 698.7 billion yuan (+11.66%) and a net profit of 163.9 billion yuan (+56.78%) [6][15] Innovative Drug Sector - The innovative drug sector's revenue for Q3 2025 reached 191.7 billion yuan (+50.66%), with a net profit of 13.1 billion yuan (+155.49%) [10] - The growth in revenue is attributed to the rapid commercialization of innovative drug products and milestone payments from product licensing [10][11] CXO Sector - The CXO sector's revenue for Q3 2025 was 247.5 billion yuan (+10.03%), with a net profit of 51.1 billion yuan (+47.69%) [15] - The sector continues to show mid-to-high-speed growth, although there is some internal differentiation among companies [15] Medical Device Sector - The medical device sector reported revenue of 1,776.8 billion yuan (-2.26%) and a net profit of 265.9 billion yuan (-14.05%) in the first three quarters of 2025 [20] - The sector is expected to recover gradually, with recommendations to focus on leading companies benefiting from domestic demand and international expansion [20] Traditional Chinese Medicine Sector - The traditional Chinese medicine sector achieved revenue of 2,548.7 billion yuan (-3.58%) and a net profit of 302.6 billion yuan (-0.85%) in the first three quarters of 2025 [18] - The sector is stabilizing, with ongoing risks from national procurement policies [18] Life Sciences Upstream - The life sciences upstream sector reported revenue of 96.6 billion yuan (+7.96%) and a net profit of 8.6 billion yuan (+32.08%) in the first three quarters of 2025 [24] - The sector is expected to see improvements in demand as inventory depletion phases out and companies increase R&D investments [25]

Market Overview - The A-share market is exhibiting a "high open, low walk, and fluctuating differentiation" pattern, with the Shanghai Composite Index maintaining above the 4000-point mark, supported by heavyweight sectors and stable policy expectations [5] - The Shenzhen Component Index is dragged down by corrections in technology stocks such as telecommunications, electronics, and computers, while the ChiNext Index is affected by pullbacks in sectors like lithium batteries, new energy vehicles, and innovative pharmaceuticals [5] Trading Dynamics - The ratio of stocks hitting the upper and lower limits shows more stocks rising than falling, indicating a relatively balanced market sentiment with a near 1:1 rise-fall ratio [6] - The consumer sector, particularly food and beverage and liquor industries, along with cyclical sectors like photovoltaic equipment and non-metallic materials, are leading the gains, while technology and financial sectors are experiencing notable adjustments [6] Market Activity - The total trading volume in both markets has decreased by 8.2%, reflecting a rise in cautious sentiment among investors, influenced by profit-taking in the large consumer sector and ongoing adjustments in high-valuation technology hardware [7] - Despite strong performances in thematic concepts like cultivated diamonds and photovoltaic equipment, these have not significantly boosted overall trading volume [7] Fund Flow and Sentiment - Institutional investors are showing a defensive and offensive differentiation, withdrawing funds from technology sectors such as consumer electronics, software development, and semiconductors, and reallocating towards undervalued blue-chip stocks (like banks) and consumer recovery sectors (such as food and beverages) [9] - Retail investors are increasingly engaging in speculative trading, with a notable focus on short-term hot sectors like photovoltaic equipment, dairy, and beverages, while some continue to chase limit-up stocks in real estate and electronic equipment sectors, indicating persistent short-term speculative sentiment [9] Investor Sentiment - Retail investor sentiment is reported at 75.85%, reflecting a strong engagement level [10] - A survey indicates that 32.25% of investors are increasing their positions, while 16.41% are reducing their holdings, and 51.34% are maintaining their current positions [14]